Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 30, 2015 2:25 AM ET

Biotechnology

Company Overview of Calypte Biomedical Corp.

Company Overview

Calypte Biomedical Corporation develops, manufactures, and distributes in vitro diagnostic tests primarily for the diagnosis of human immunodeficiency virus (HIV) infection. The company focuses on the commercialization of HIV-1/2 rapid test products for the rapid detection of antibodies to HIV-1 and HIV Type 2 in oral fluid using a lateral flow dipstick design. Its products also comprise Aware HIV-1/2 OMT test to address the drawbacks of blood testing; and Aware HIV-1/2 Oral OTC test, which is an over-the-counter version of oral fluid rapid test. In addition, the company provides Aware BED HIV-1 Incidence Test that is used to estimate the rate of new HIV infections in a population by determi...

15875 SW 72nd Avenue

Portland, OR 97224

United States

Founded in 1988

3 Employees

Phone:

503-726-2227

Fax:

503-601-6299

Key Executives for Calypte Biomedical Corp.

Chairman, Chief Executive Officer, President and Member of Nominating Committee
Age: 69
Chief Financial Officer, Principal Accounting Officer, Vice President, Secretary and Director
Age: 41
President of Geneva Branch Office
Vice President
Vice President of Sales and Marketing
Age: 69
Compensation as of Fiscal Year 2015.

Calypte Biomedical Corp. Key Developments

SEC Revokes Registration Of Securities Of Calypte Biomedical Corporation For Failure To Make Required Periodic Filings

Securities and Exchange Commission (SEC or the commission) revoked the registration of each class of the registered securities of Calypte Biomedical Corporation for failure to make required periodic filings with the Commission. SEC reported that the company failed to comply with Section 13(a) of the Securities Exchange Act of 1934 (Exchange Act) and Rules 13a-1 and 13a-13 there under and revoking the registration of each class of the company’s securities pursuant to Section 12(j) of the Exchange Act.

SEC Orders Hearings On Registration Suspension Or Revocation Against Calypte Biomedical Corporation For Failure To Make Required Periodic Filings

Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Calypte Biomedical Corporation for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.

Calypte Biomedical Corp. Auditor Raises 'Going Concern' Doubt

Calypte Biomedical Corp. filed its 10-K on Jun 24, 2014 for the period ending Dec 31, 2012. In this report its auditor, Odenberg Ullakko Muranishi & Co LLP - OUM & Co LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Similar Private Companies By Industry

Company Name Region
Clarassance, Inc. United States
Omniome, Inc. United States
AIKO Biotechnology, Inc. United States
Therapeutic Systems Research Laboratories, Inc. United States
Amylin Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Calypte Biomedical Corp., please visit www.calypte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.